Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.53.
During the past 3 years, the average EBIT per Share Growth Rate was 25.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 10.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Medivir AB's EBIT per Share or its related term are showing as below:
OSTO:MVIR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.2 Med: 12.9 Max: 116
Current: 25.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Medivir AB was 116.00% per year. The lowest was -40.20% per year. And the median was 12.90% per year.
OSTO:MVIR's 3-Year EBIT Growth Rate is ranked better than 62.66% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs OSTO:MVIR: 25.70
Medivir AB's EBIT for the
three
months ended in Mar. 2026 was kr-9.50 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medivir AB EBIT per Share Related Terms
Medivir AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Medivir AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (OSTO:MVIR) has a EBIT per Share of kr-0.53 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medivir AB and its competitors. According to the industry distribution chart, Medivir AB ranks #438 out of 1173 companies in the Biotechnology industry, placing it in the top 37.3%.
Is Medivir AB's EBIT per Share too high?
Medivir AB's current EBIT per Share is kr-0.53. Based on the distribution chart, Medivir AB ranks #438 out of 1173 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #438 out of 1173 companies for EBIT per Share. This puts Medivir AB in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current EBIT per Share is kr-0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current EBIT per Share is kr-0.53. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current EBIT per Share is kr-0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (OSTO:MVIR) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for OSTO:MVIR:
EBIT per Share: kr-0.53
GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score
Get the complete analysis for OSTO:MVIR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MVIR has been successfully added to your 
